Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1811 entries
Sorted by: Best Match Show Resources per page
… . Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept …

Graduate training programs stem

[No authors listed]
GSID: R8quIcNZFU8J
V Nock - page-meeting.org

… In a clinical study 17 patients received a combination therapy of carboplatin (C), etoposide (E) and thiotepa (T) including a stem cell rescue consisting of peripheral blood stem cell …

Cite
Nock, V. Leukopenia following triple high-dose chemotherapy and stem cell rescue V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1)(1) Dept. Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept. Clinical Pharmacy, University of Bonn, Bonn, Germany.
Nock, Valerie. "Leukopenia following triple high-dose chemotherapy and stem cell rescue V. Nock (1, 2), A. Lindauer (3), U. Jaehde (3), C. Kloft (1)(1) Dept. Clinical Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg/Freie Universitaet Berlin, Germany (2) and Graduate Research Training Program PharMetrX (3) Dept. Clinical Pharmacy, University of Bonn, Bonn, Germany."
Copy Download .nbib Format: MLA
Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Thoracic cancer

Shi Y, Hu Y, Hu X, Li X, Lin L, Han X.
PMID: 26557919
Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20.

BACKGROUND: This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). The relationship between UGT1A1 genotypes and patient outcomes was also...

Cite
Shi Y, Hu Y, Hu X, et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6(6):785-91doi: 10.1111/1759-7714.12303.
Shi, Y., Hu, Y., Hu, X., Li, X., Lin, L., & Han, X. (2015). Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thoracic cancer, 6(6), 785-91. https://doi.org/10.1111/1759-7714.12303
Shi, Yuankai, et al. "Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial." Thoracic cancer vol. 6,6 (2015): 785-91. doi: https://doi.org/10.1111/1759-7714.12303
Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20. PMID: 26557919; PMCID: PMC4632933.
Copy Download .nbib Format: NLM
Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

Oncology letters

Kawasaki K, Hamamoto Y, Suzuki T, Hirata K, Sukawa Y, Kasuga A, Hayashi Y, Takaishi H, Kameyama K, Kanai T.
PMID: 28927133
Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18.

Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based...

Cite
Kawasaki K, Hamamoto Y, Suzuki T, et al. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017;14(3):3697-3700doi: 10.3892/ol.2017.6601.
Kawasaki, K., Hamamoto, Y., Suzuki, T., Hirata, K., Sukawa, Y., Kasuga, A., Hayashi, Y., Takaishi, H., Kameyama, K., & Kanai, T. (2017). Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncology letters, 14(3), 3697-3700. https://doi.org/10.3892/ol.2017.6601
Kawasaki, Kenta, et al. "Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report." Oncology letters vol. 14,3 (2017): 3697-3700. doi: https://doi.org/10.3892/ol.2017.6601
Kawasaki K, Hamamoto Y, Suzuki T, Hirata K, Sukawa Y, Kasuga A, Hayashi Y, Takaishi H, Kameyama K, Kanai T. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18. PMID: 28927133; PMCID: PMC5587936.
Copy Download .nbib Format: NLM
Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report.

Surgical case reports

Aoyagi K, Kizaki J, Isobe T, Akagi Y.
PMID: 26943449
Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24.

A 69-year-old man was referred to our institution for treatment of gastric cancer. Type 2 gastric cancer was found on the anterior wall of the lower body of the stomach.The patient underwent distal gastrectomy, D2 lymph node dissection, and...

Cite
Aoyagi K, Kizaki J, Isobe T, et al. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015;1(1):125doi: 10.1186/s40792-015-0126-1.
Aoyagi, K., Kizaki, J., Isobe, T., & Akagi, Y. (2015). Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surgical case reports, 1(1), 125. https://doi.org/10.1186/s40792-015-0126-1
Aoyagi, Keishiro, et al. "Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report." Surgical case reports vol. 1,1 (2015): 125. doi: https://doi.org/10.1186/s40792-015-0126-1
Aoyagi K, Kizaki J, Isobe T, Akagi Y. Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report. Surg Case Rep. 2015 Dec;1(1):125. doi: 10.1186/s40792-015-0126-1. Epub 2015 Dec 24. PMID: 26943449; PMCID: PMC4690825.
Copy Download .nbib Format: NLM
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Gynecologic oncology reports

Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA.
PMID: 28393092
Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May.

OBJECTIVE: Ovarian anaplastic ependymoma is a rare gynecologic malignancy that poses diagnostic and treatment challenges. Treatment of sub-optimally debulked disease usually portends poor prognosis. Molecular testing of tumor specimen can identify more specific targets for additional therapy such as...

Cite
Gorski JW, Taylor JS, Zhang J, et al. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017;20:93-96doi: 10.1016/j.gore.2017.03.005.
Gorski, J. W., Taylor, J. S., Zhang, J., Liu, J., & Jazaeri, A. A. (2017). Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic oncology reports, 2093-96. https://doi.org/10.1016/j.gore.2017.03.005
Gorski, Justin Wayne, et al. "Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole." Gynecologic oncology reports vol. 20 (2017): 93-96. doi: https://doi.org/10.1016/j.gore.2017.03.005
Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May. PMID: 28393092; PMCID: PMC5376265.
Copy Download .nbib Format: NLM
Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient.

Journal of nephropathology

Ventura Aguiar P, Dias C, Azevedo P, Silva HN, Almeida M, Pedroso S, Martins LS, Dias L, Rodrigues A, Viscaíño R, Cabrita A, Henriques AC.
PMID: 26312238
J Nephropathol. 2015 Jul;4(3):97-100. doi: 10.12860/jnp.2015.18. Epub 2015 Jul 01.

BACKGROUND: Histiocytic sarcoma (HS) is a rare hematologic neoplasm with a few hundred cases having been described to date.CASE PRESENTATION: We report the case of a 56-year-old woman with a history of hepatitis C infection and chronic kidney disease...

Cite
Ventura Aguiar P, Dias C, Azevedo P, et al. Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. J Nephropathol. 2015;4(3):97-100doi: 10.12860/jnp.2015.18.
Ventura Aguiar, P., Dias, C., Azevedo, P., Silva, H. N., Almeida, M., Pedroso, S., Martins, L. S., Dias, L., Rodrigues, A., Viscaíño, R., Cabrita, A., & Henriques, A. C. (2015). Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. Journal of nephropathology, 4(3), 97-100. https://doi.org/10.12860/jnp.2015.18
Ventura Aguiar, Pedro, et al. "Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient." Journal of nephropathology vol. 4,3 (2015): 97-100. doi: https://doi.org/10.12860/jnp.2015.18
Ventura Aguiar P, Dias C, Azevedo P, Silva HN, Almeida M, Pedroso S, Martins LS, Dias L, Rodrigues A, Viscaíño R, Cabrita A, Henriques AC. Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. J Nephropathol. 2015 Jul;4(3):97-100. doi: 10.12860/jnp.2015.18. Epub 2015 Jul 01. PMID: 26312238; PMCID: PMC4544561.
Copy Download .nbib Format: NLM
A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.

Transplantation direct

Shigematsu A, Ozawa Y, Onizuka M, Fujisawa S, Suzuki R, Atsuta Y, Hatanaka K, Masuko M, Ito T, Kobayashi N, Kato J, Miyamura K, Fukuda T, Morishima Y, Imamura M.
PMID: 27500214
Transplant Direct. 2015 Mar 13;1(2):e8. doi: 10.1097/TXD.0000000000000514. eCollection 2015 Mar.

UNLABELLED: Prognosis for adult patients with acute lymphoblastic leukemia (ALL) has been reported to be approximately 35% to 50%, even after allogeneic stem cell transplantation (allo-SCT). We previously reported retrospective analyses of a conditioning regimen of medium-dose etoposide, cyclophosphamide...

Cite
Shigematsu A, Ozawa Y, Onizuka M, et al. A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplant Direct. 2015;1(2):e8doi: 10.1097/TXD.0000000000000514.
Shigematsu, A., Ozawa, Y., Onizuka, M., Fujisawa, S., Suzuki, R., Atsuta, Y., Hatanaka, K., Masuko, M., Ito, T., Kobayashi, N., Kato, J., Miyamura, K., Fukuda, T., Morishima, Y., & Imamura, M. (2015). A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplantation direct, 1(2), e8. https://doi.org/10.1097/TXD.0000000000000514
Shigematsu, Akio, et al. "A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia." Transplantation direct vol. 1,2 (2015): e8. doi: https://doi.org/10.1097/TXD.0000000000000514
Shigematsu A, Ozawa Y, Onizuka M, Fujisawa S, Suzuki R, Atsuta Y, Hatanaka K, Masuko M, Ito T, Kobayashi N, Kato J, Miyamura K, Fukuda T, Morishima Y, Imamura M. A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. Transplant Direct. 2015 Mar 13;1(2):e8. doi: 10.1097/TXD.0000000000000514. eCollection 2015 Mar. PMID: 27500214; PMCID: PMC4946459.
Copy Download .nbib Format: NLM
Bleomycin-induced flagellate erythema: A case report and review of the literature.

Oncology letters

Lee HY, Lim KH, Ryu Y, Song SY.
PMID: 25009666
Oncol Lett. 2014 Aug;8(2):933-935. doi: 10.3892/ol.2014.2179. Epub 2014 May 26.

Bleomycin has been used most commonly in the treatment of Hodgkin's lymphoma, certain germ cell tumors (GCT) and for the sclerosis of recurrent pleural effusions. Bleomycin toxicity predominantly affects the skin and lungs. Skin toxicity includes Raynaud's phenomenon, hyperkeratosis,...

Cite
Lee HY, Lim KH, Ryu Y, et al. Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncol Lett. 2014;8(2):933-935doi: 10.3892/ol.2014.2179.
Lee, H. Y., Lim, K. H., Ryu, Y., & Song, S. Y. (2014). Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncology letters, 8(2), 933-935. https://doi.org/10.3892/ol.2014.2179
Lee, Hui-Young, et al. "Bleomycin-induced flagellate erythema: A case report and review of the literature." Oncology letters vol. 8,2 (2014): 933-935. doi: https://doi.org/10.3892/ol.2014.2179
Lee HY, Lim KH, Ryu Y, Song SY. Bleomycin-induced flagellate erythema: A case report and review of the literature. Oncol Lett. 2014 Aug;8(2):933-935. doi: 10.3892/ol.2014.2179. Epub 2014 May 26. PMID: 25009666; PMCID: PMC4081419.
Copy Download .nbib Format: NLM
Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts.

Genes

Yan H, Tammaro M, Liao S.
PMID: 27376333
Genes (Basel). 2016 Jul 01;7(7). doi: 10.3390/genes7070032.

Topoisomerase 2 (Top2) is an essential enzyme responsible for manipulating DNA topology during replication, transcription, chromosome organization and chromosome segregation. It acts by nicking both strands of DNA and then passes another DNA molecule through the break. The 5'...

Cite
Yan H, Tammaro M, Liao S. Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes (Basel). 2016;7(7)doi: 10.3390/genes7070032.
Yan, H., Tammaro, M., & Liao, S. (2016). Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes, 7(7), . https://doi.org/10.3390/genes7070032
Yan, Hong, et al. "Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts." Genes vol. 7,7 (2016). doi: https://doi.org/10.3390/genes7070032
Yan H, Tammaro M, Liao S. Collision of Trapped Topoisomerase 2 with Transcription and Replication: Generation and Repair of DNA Double-Strand Breaks with 5' Adducts. Genes (Basel). 2016 Jul 01;7(7). doi: 10.3390/genes7070032. PMID: 27376333; PMCID: PMC4962002.
Copy Download .nbib Format: NLM
Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.

International journal of clinical and experimental medicine

Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, Bag HG.
PMID: 26629149
Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015.

High-dose chemotherapy (HDC) applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with malignant lymphoma. At present, there is a limited number of studies which compare toxicity and efficacy of various high-dose...

Cite
Berber I, Erkurt MA, Nizam I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015;8(9):16308-14
Berber, I., Erkurt, M. A., Nizam, I., Koroglu, M., Kaya, E., Kuku, I., & Bag, H. G. (2015). Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. International journal of clinical and experimental medicine, 8(9), 16308-14.
Berber, Ilhami, et al. "Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience." International journal of clinical and experimental medicine vol. 8,9 (2015): 16308-14.
Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, Bag HG. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015. PMID: 26629149; PMCID: PMC4659037.
Copy Download .nbib Format: NLM
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?.

Journal of Cancer

Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K.
PMID: 25767606
J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015.

PURPOSE: Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Furthermore, somatostatin (SST) receptors (SSTR1, 2A and B, 3, 4...

Cite
Domvri K, Bougiouklis D, Zarogoulidis P, et al. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015;6(4):360-6doi: 10.7150/jca.11308.
Domvri, K., Bougiouklis, D., Zarogoulidis, P., Porpodis, K., Xristoforidis, M., Liaka, A., Eleutheriadou, E., Lampaki, S., Lazaridis, G., Organtzis, J., Kyriazis, G., Hohenforst-Schmidt, W., Tsirgogianni, K., Karavasilis, V., Baka, S., Darwiche, K., Freitag, L., Trakada, G., & Zarogoulidis, K. (2015). Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. Journal of Cancer, 6(4), 360-6. https://doi.org/10.7150/jca.11308
Domvri, Kalliopi, et al. "Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?." Journal of Cancer vol. 6,4 (2015): 360-6. doi: https://doi.org/10.7150/jca.11308
Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?. J Cancer. 2015 Feb 23;6(4):360-6. doi: 10.7150/jca.11308. eCollection 2015. PMID: 25767606; PMCID: PMC4349876.
Copy Download .nbib Format: NLM
Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis.

Molecular and clinical oncology

Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L.
PMID: 25798279
Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25.

This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small-cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and...

Cite
Yang H, Ma Y, Liu Z, et al. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2014;3(2):420-424doi: 10.3892/mco.2014.467.
Yang, H., Ma, Y., Liu, Z., Wang, Z., Han, B., & Ma, L. (2015). Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Molecular and clinical oncology, 3(2), 420-424. https://doi.org/10.3892/mco.2014.467
Yang, Huizhen, et al. "Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis." Molecular and clinical oncology vol. 3,2 (2015): 420-424. doi: https://doi.org/10.3892/mco.2014.467
Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2015 Mar;3(2):420-424. doi: 10.3892/mco.2014.467. Epub 2014 Nov 25. PMID: 25798279; PMCID: PMC4360815.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1811 entries